BridgeBio Oncology Therapeutics, Inc. – Annual Report Summary for Investors

BridgeBio Oncology Therapeutics, Inc. (BBOT) is an early-stage biopharmaceutical company on a mission to discover and develop precision treatments for cancer, with a primary focus on RAS-dependent cancers. Founded as TheRas, Inc. in August 2016 under BridgeBio Pharma Inc., the company quickly secured an exclusive license agreement with UCSF in September 2016 for foundational technologies crucial to its early drug development. BBOT began operating more independently from BridgeBio Pharma on April 30, 2024.

A significant milestone for BBOT occurred on August 11, 2025, when it completed a "de-SPAC Transaction" by combining with Helix Acquisition Corp. II. This transaction brought BBOT to the public market, and the combined entity now trades on Nasdaq under the ticker symbol "BBOT." This move typically provides a vital infusion of capital and increased visibility, both critical for a development-stage biotech company.

Current Operations and Pipeline

BBOT is intensely focused on research and development (R&D). The company currently has three key product candidates in Phase 1 clinical trials: BBO-8520, BBO-10203, and BBO-11818, alongside broader discovery programs. On January 7, 2026, BBOT reported encouraging preliminary safety and early anti-tumor data for all three candidates, marking an important step forward in their clinical journey.

Financial Performance and Health

As an early-stage biopharmaceutical company, BBOT has not generated any revenue from product sales to date, as it does not yet have any approved products. Consequently, the company has incurred substantial losses, primarily driven by significant R&D expenditures.

• For the year ended December 31, 2025, BBOT reported a net loss of $134.0 million, a notable increase from the $74.3 million net loss in 2024.
• The company's accumulated deficit reached $356.6 million as of December 31, 2025, reflecting its history of investment in drug development.
• BBOT expects to continue incurring significant losses for the foreseeable future as it advances its drug candidates through costly clinical development.

BBOT estimates its current cash, cash equivalents, and short-term investments are sufficient to fund operations and expenses into early 2028. This estimate, however, does not account for potential product sales revenue and relies on assumptions that could change. As of August 13, 2025, the market valued the company's publicly traded shares (excluding insider holdings) at approximately $465 million, with about 80 million shares of common stock outstanding as of March 2, 2026.

BBOT is classified as a 'non-accelerated filer,' a 'smaller reporting company,' and an 'emerging growth company.' These designations indicate its relatively young and smaller public company status, often implying fewer resources and a less extensive operating history compared to larger, more established firms. The company carries no significant long-term debt as of the reporting period, relying primarily on equity financing for its operations.

Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A Highlights)

Management's discussion highlights the company's financial condition and results, primarily shaped by its status as an early-stage biopharmaceutical company.

Results of Operations: BBOT has not generated any revenue from product sales. Its operations have resulted in significant net losses, primarily due to substantial research and development (R&D) expenses and general and administrative (G&A) costs. R&D expenses reflect the company's core mission of advancing its pipeline candidates through preclinical and clinical development, including costs associated with clinical trials, manufacturing clinical supplies, and personnel.

The net loss increased from $74.3 million in 2024 to $134.0 million in 2025. This increase primarily stems from the expanded scale of clinical trial activities for its three Phase 1 candidates. Associated personnel and operational costs also rose as the company ramped up its independent operations and public company infrastructure following the de-SPAC transaction. G&A expenses also increased to support public company compliance, legal, accounting, and administrative functions.

Liquidity and Capital Resources: The company's primary source of liquidity has been capital raised through equity financings, including proceeds from the de-SPAC transaction. As of December 31, 2025, BBOT held cash, cash equivalents, and short-term investments sufficient to fund operations into early 2028. This estimate is based on current operating plans and does not account for potential future business development activities or significant changes in the pace of clinical development. The company anticipates requiring substantial additional capital to complete the development and commercialization of its product candidates. Management continuously evaluates various financing alternatives, including equity offerings, debt financing, and strategic collaborations, to secure the necessary funding. The ability to obtain additional financing will depend on market conditions, the progress of its clinical programs, and other factors.

Critical Accounting Policies: Key accounting policies include those related to research and development expenses, which BBOT expenses as incurred, and stock-based compensation. Management's estimates and judgments are particularly important in areas such as accruing clinical trial expenses and valuing stock options and other equity awards.

Strategy and Future Outlook

BBOT's core strategy revolves around successfully advancing its current pipeline through clinical trials, ultimately seeking regulatory approvals and commercialization. The company aims to build out its capabilities in manufacturing, sales, and marketing as it progresses. Its future hinges on achieving numerous complex objectives, including successful trial completion, regulatory approvals, establishing manufacturing, and securing market acceptance and reimbursement. BBOT also plans to continue expanding its team and attracting talent to support its growth.

The company will require significantly more capital beyond its current runway to fully develop and commercialize its product candidates. Potential future funding sources include equity financing (which could dilute current investors), debt, or strategic partnerships. However, there is no guarantee that such funding will be available when needed or on favorable terms.

Competitive Position

BBOT operates in the highly competitive oncology market, specifically focusing on precision oncology for RAS-dependent cancers. This is an emerging field, and the company faces competition from numerous larger, more established pharmaceutical and biotechnology companies. These competitors often possess greater financial resources, more extensive R&D capabilities, and broader commercial infrastructures. The success of BBOT's approach also depends on the acceptance of targeted cancer therapies and the ability to accurately identify specific patient populations for its drugs.

Key Risks for Investors

Investing in BBOT involves a high degree of risk, characteristic of early-stage biopharmaceutical companies:

• Limited Operating History & No Revenue: BBOT has a short history as an independent public entity, no approved products, and no revenue, making future success difficult to predict.
• Significant and Continuing Losses: The company has incurred substantial losses and expects this trend to continue, requiring ongoing capital investment.
• Need for Additional Capital & Dilution Risk: While BBOT has cash into early 2028, it will need substantial additional funding to complete drug development. There is no guarantee of securing this funding, and raising capital through equity sales could dilute existing shareholders.
• High Uncertainty in Drug Development:
  • Clinical Trial Risks: The process is long, expensive, and uncertain. Phase 1 trials may not succeed, and many drug candidates fail to reach approval. Delays, negative results, or patient enrollment issues are common.
  • Regulatory Hurdles: BBOT lacks experience with large-scale approvals. Regulatory processes are unpredictable, and approval can be denied for various reasons, including safety, efficacy, or manufacturing concerns. Even if approved, drugs may face significant usage restrictions.
  • Combination Therapy Risks: Developing drugs for use with other therapies (approved or unapproved) introduces additional dependencies and risks related to the partner drug's performance, availability, and cost.
• Intellectual Property (IP) Risks:
  • Protection Challenges: Difficulty in obtaining, maintaining, and enforcing strong patent protection could allow competitors to copy BBOT's innovations.
  • Patent Term Extensions: The ability to secure and maximize patent term extensions (e.g., via the Hatch-Waxman Act) is crucial for market exclusivity, but not guaranteed.
  • Disputes: "Derivation proceedings" or other IP disputes could be costly and detrimental.
• Reliance on Third Parties & Supply Chain: BBOT depends heavily on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties for critical aspects of its operations.
  • Sole-Source Suppliers: Dependence on single suppliers for critical materials (like Active Pharmaceutical Ingredients) creates significant supply chain risk. While BBOT is working on backup suppliers, their availability and timeliness are not guaranteed.
  • Quality Control: Issues with third-party quality, consistency, or regulatory compliance could lead to delays, product defects, or trial termination.
• Market Size and Niche Focus Risks: BBOT's focus on specific RAS-dependent cancers means its potential patient populations might be smaller than estimated. The actual market size depends on diagnostic criteria, medical acceptance, patient access, and reimbursement policies, all of which are uncertain.
• Talent and Management Risks: As a growing company, BBOT faces intense competition for skilled scientific, clinical, and management personnel. Loss of key executives or inability to attract top talent could severely impact its operations.
• Regulatory and Industry Environment: The unpredictable regulatory landscape, potential for increased government regulation due to negative industry events, and public perception issues regarding cancer therapies could significantly impact BBOT's path to market. New data regulations (e.g., U.S. DOJ Bulk Data Rule) and trade policies could also affect international collaborations and supply chains.
• Economic Conditions: General economic instability, such as high inflation or interest rates, could make it harder or more expensive for BBOT to raise necessary capital.

BBOT's success is highly speculative and depends on its ability to navigate these significant scientific, clinical, regulatory, financial, and operational challenges.